Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.

Autor:	Mahajan I; Department of Oncology, Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust, Lincoln, Lincolnshire, UK., Kadam A; Government Cuddalore Medical College and Hospital, Chidambaram, India.; All authors contributed equally., McCann L; Department of Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University, London, UK.; All authors contributed equally., Ghose A; Department of Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK.; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.; United Kingdom and Ireland Global Cancer Network.; Prevention, Screening and Early Detection Network, European Cancer Organisation, Brussels, Belgium.; All authors contributed equally., Wakeham K; Department of Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.; United Kingdom and Ireland Global Cancer Network.; Radiotherapy UK., Dhillon NS; Department of General Surgery, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, Lincolnshire, UK., Stanway S; United Kingdom and Ireland Global Cancer Network.; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK., Boussios S; Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK.; Faculty of Life Sciences and Medicine, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.; Kent and Medway Medical School, University of Kent, Canterbury, UK.; Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, UK.; AELIA Organisation, Thessaloniki, Greece., Banerjee S; Department of Radiation Oncology, IPGMER and SSKM Hospital, Kolkata, India., Priyadarshini A; Department of Preventive and Social Medicine, VMMC and Safdarjung Hospital, New Delhi, India., Sirohi B; United Kingdom and Ireland Global Cancer Network.; Department of Medical Oncology, BALCO Medical Centre, Vedanta Medical Research Foundation, Chattisgarh, India.; Joint Senior Authors., Torode JS; Institute of Cancer Policy, Centre for Cancer, Society & Public Health, King's College London, London, UK.; Joint Senior Authors., Mitra S; Department of Radiation Oncology, Fortis Medical Research Institute, Gurgaon, India.; Joint Senior Authors.
Jazyk:	angličtina
Zdroj:	Ecancermedicalscience [Ecancermedicalscience] 2024 Sep 11; Vol. 18, pp. 1762. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
DOI:	10.3332/ecancer.2024.1762
Abstrakt:	Cervical cancer (CC) is one of the highest prevailing causes of female cancer-related mortality globally. A significant discrepancy in incidence has been noted between high and low-middle-income countries. The origins of CC have been accredited to the human papillomavirus (HPV) with serotypes 16 and 18 being the most prevalent. HPV vaccines, with 90%-97% efficacy, have proven safe and currently function as the primary prevention method. In addition, secondary prevention by timely screening can potentially increase the 5-year survival rate by >90%. High-precision HPV DNA testing has proven to be both highly sensitive and specific for early detection and is advocated by the WHO. Lack of public awareness, poor screening infrastructure and access to vaccines, socio-cultural concerns, along with economic, workforce-associated barriers and the presence of marginalised communities unable to access services have contributed to a continued high incidence. This article comprehensively analyses the efficacy, coverage, benefits and cost-effectiveness of CC vaccines and screening strategies including the transition from cytological screening to HPV self-sampling, while simultaneously exploring the real-world disparities in their feasibility. Furthermore, it calls for the implementation of population-based approaches that address the obstacles faced in approaching the WHO 2030 targets for CC elimination. Competing Interests: No conflict of interest. (© the authors; licensee ecancermedicalscience.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu